Edgewise Therapeutics, Inc. (EWTX)

NASDAQ: EWTX · Real-Time Price · USD

13.35

-0.39 (-2.84%)

Aug 6, 2025, 1:02 PM - Market open

Sage Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2020
Period Ending	Mar '25 Mar 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2020
Selling, General & Admin	34.01	31.87	23.45	17.63	11.03	2.21	Upgrade
Research & Development	136.03	126.97	90.91	54.03	32.19	14.98	Upgrade
Operating Expenses	170.04	158.83	114.36	71.66	43.22	17.19	Upgrade
Operating Income	-170.04	-158.83	-114.36	-71.66	-43.22	-17.19	Upgrade
Interest & Investment Income	23.95	25.02	14.19	4.02	0.4	0.07	Upgrade
Pretax Income	-146.09	-133.81	-100.16	-67.64	-42.81	-17.12	Upgrade
Net Income	-146.09	-133.81	-100.16	-67.64	-42.81	-17.12	Upgrade
Net Income to Common	-146.09	-133.81	-100.16	-67.64	-42.81	-17.12	Upgrade
Shares Outstanding (Basic)	94	92	64	54	38	1	Upgrade
Shares Outstanding (Diluted)	94	92	64	54	38	1	Upgrade
Shares Change (YoY)	35.11%	45.02%	18.90%	42.82%	4977.96%	95.63%	Upgrade
EPS (Basic)	-1.55	-1.45	-1.57	-1.26	-1.14	-23.17	Upgrade
EPS (Diluted)	-1.55	-1.45	-1.57	-1.26	-1.14	-23.17	Upgrade
Free Cash Flow	-119.36	-110.34	-97.69	-58.18	-34.18	-14.84	Upgrade
Free Cash Flow Per Share	-1.27	-1.19	-1.53	-1.09	-0.91	-20.08	Upgrade
EBITDA	-167.93	-156.76	-112.81	-71.29	-42.94	-17.01	Upgrade
D&A For EBITDA	2.11	2.07	1.55	0.37	0.27	0.19	Upgrade
EBIT	-170.04	-158.83	-114.36	-71.66	-43.22	-17.19	Upgrade

Updated May 8, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q